Latest news with #NCE
Time of India
3 days ago
- Business
- Time of India
BAI unveils Rs 9.75 crore plan to develop grassroots, support coaches and reward medallists
NEW DELHI: Offering monthly retainers to former international coaches, doubling domestic tournament prize money and rewarding international medal-winning performances are part of an investment plan announced by the Badminton Association of India (BAI) as it unveiled a Rs 9.75 crore annual plan to drive the growth of sport in the country. The decision was taken at BAI's Annual General Body Meeting held in the national capital on Saturday. Go Beyond The Boundary with our YouTube channel. SUBSCRIBE NOW! With an eye on long-term talent development and international success, the federation allocated Rs 73 lakh to offer monthly retainers to Olympians and former internationals who are now training players at national camps, and earmarked Rs 2.22 crore as direct rewards for Indian shuttlers who win medals at prestigious global events. Out of the Rs 9.75 crore which BAI will spend annually for grassroots initiatives and to help state associations conduct domestic tournaments, the total prize pool and grant allocation for national tournaments stands at Rs 3.8 crore. Under the revised structure, annual grants to state associations have been increased from Rs 7.5 lakh to Rs 10 lakh. BAI will also provide additional support for organising national ranking tournaments across age groups — Rs 3 lakh for U-15 and U-17 events, Rs 2 lakh for Senior and U-19, and Rs 1.5 lakh for U-13. 'Given the size of our country, one NCE was never going to be enough and hence we are providing grants to state associations to come up with development across the state and the current increase in grant will help them enhance their existing programs,' said BAI president Himanta Biswa Sarma . To enhance domestic competition, prize money for national ranking tournaments has been doubled. Senior national ranking events will now offer Rs 10 lakh in prize money, while U-19 events will get Rs 8 lakh, U-15 and U-17 Rs 12 lakh, and U-13 Rs 6 lakh. The total allocation for all National Championships has jumped from Rs 2.13 crore to Rs 3.2 crore, with the Senior Nationals alone seeing an increase from Rs 75 lakh to Rs 1 crore. BAI has also made financial provisions for paying Rs 1 lakh per month to Olympians and Rs 50,000 per month to coaches who have represented the official Indian team in international events and are currently coaching at National Camps held across three locations. To reward international excellence, a cash prize of Rs 20 lakh will be given to a World Championship gold medallist, Rs 10 lakh for a BWF Super 1000 title, and Rs 50 lakh for a team gold at the senior level. Junior team golds will attract Rs 30 lakh, while individual gold medallists at junior World and Asian Championships will receive Rs 15 lakh and Rs 10 lakh respectively. "The needs of up-and-coming players, motivating them and providing them better financial incentives was critical for the development of the sport and chart out a pathway through which the future course,' said Sarma.
News18
3 days ago
- Business
- News18
BAI's 9.75 Crore Plan To Boost Grassroots, Support Coaches & Reward Medallists
Last Updated: The Badminton Association of India announced a plan to boost the sport, including monthly retainers for ex-coaches, doubling domestic prizes, and rewarding medalists. The Badminton Association of India (BAI) has announced an INR 9.75 crore annual investment plan to boost the sport's growth in the country. This plan includes offering monthly retainers to former international coaches, doubling prize money for domestic tournaments, and rewarding international medal-winning performances. The decision was made during BAI's Annual General Meeting held in the national capital on Saturday. To focus on long-term talent development and international success, the federation has allocated INR 73 lakh for monthly retainers to Olympians and former internationals who now train players at national camps. Additionally, INR 2.22 crore has been set aside as direct rewards for Indian shuttlers who win medals at major global events. Out of the INR 9.75 crore annual expenditure for grassroots initiatives and assisting state associations in conducting domestic tournaments, INR 3.8 crore has been dedicated to the total prize pool and grant allocation for national tournaments. The revised structure increases annual grants to state associations from INR 7.5 lakh to INR 10 lakh. BAI will also provide additional support for organising national ranking tournaments across various age groups: INR 3 lakh for U-15 and U-17 events, INR 2 lakh for Senior and U-19 events, and INR 1.5 lakh for U-13 events. BAI president Himanta Biswa Sarma stated that given the size of the country, one National Centre of Excellence (NCE) was insufficient. Thus, increased grants to state associations will help them enhance their existing programmes. To improve domestic competition, the prize money for national ranking tournaments has been doubled. Senior national ranking events will now offer INR 10 lakh in prize money, U-19 events will offer INR 8 lakh, U-15 and U-17 events will offer INR 12 lakh, and U-13 events will offer INR 6 lakh. The total allocation for all National Championships has increased from INR 2.13 crore to INR 3.2 crore, with the Senior Nationals alone seeing an increase from INR 75 lakh to INR 1 crore. BAI has also allocated INR 1 lakh per month to Olympians and INR 50,000 per month to coaches who have represented the official Indian team in international events and are currently coaching at National Camps held across three locations. To reward international excellence, a cash prize of INR 20 lakh will be given to a World Championship gold medallist, INR 10 lakh for a BWF Super 1000 title, and INR 50 lakh for a team gold at the senior level. Junior team golds will attract INR 30 lakh, while individual gold medallists at junior World and Asian Championships will receive INR 15 lakh and INR 10 lakh, respectively. Sarma emphasised that addressing the needs of up-and-coming players and providing better financial incentives is crucial for the sport's development and for charting a successful future path.
Hans India
21-05-2025
- Sport
- Hans India
AIFF Player of the Year Subhasish Bose 'motivated to work harder' after dream season
Kolkata: A tremendously successful domestic season with Mohun Bagan Super Giant, capped off with the coveted AIFF Men's Player of the Year Award, has only fuelled defender Subhasish Bose's hunger for more success in India's blue during the June FIFA International Window. The Blue Tigers began training for the friendly against Thailand (June 4) and the AFC Asian Cup Qualifier against Hong Kong (June 10), on Monday at the AIFF National Centre of Excellence in Kolkata, Bose's hometown. "Yes, the year has gone very well for me, and this kind of season always helps boost the confidence of any player. It also motivates me to work harder and improve myself, so that I can play better for my country. We've got two international matches in front of us, and we want to give our best in these matches and try to get the desired results for India," Bose told reporters during the training session in Kolkata. "I'm especially happy that the camp is being held in Kolkata, and that AIFF has made efforts to make facilities such as the NCE here, so that the national team can train on quality pitches such as the ones we get here," said the 29-year-old. Bose has 42 caps for the senior national team so far, and is aiming to represent India in a third consecutive AFC Asian Cup. From playing every single minute during the 2019 Asian Cup in the UAE as a 23-year-old, his seven-year journey with the Blue Tigers until now has been a hallmark of consistency. "I consider myself to be fortunate to be able to play for the nation. Not all matches are the same, but all are important. Sometimes you do well, sometimes you don't. That's part of the game. What's important is that we all work together and play as a unit, then not only can we get the clean sheets, but also score goals.' Bose was the third-highest Indian scorer in the Indian Super League this season with six goals, emphatic numbers for a left-back. While he still eyes his first for the country, as long as India score and keep clean sheets, all will be well. "I believe that we have a lot of talented and creative players who can score goals. Even Sunil (Chhetri) bhai is back, so I hope that in the next two matches, we score goals, and also defend in a compact manner and get clean sheets,' he said. "Perhaps we've made some small mistakes over the last few matches. But that's what we're here to work on. We need to improve ourselves in these areas before approaching the two matches ahead. Coach has been discussing the areas of improvement with us during this camp, and we are all training to get better in such areas," Bose said. Over a week of training in Kolkata, followed by six days in Thailand, is a healthy amount of time to prepare for the friendly game ahead of the all-important qualifier in Hong Kong. After a long and busy domestic season, culminating with the Kalinga Super Cup on May 3, the players had a brief rest period before getting back to the grind. "We've all played for different clubs over the season, but we try to gel well together, which is very important because we've all played under different systems under different coaches. Now we have to settle into the system that coach Manolo has laid out for us so that we perform better in a collective manner. "Playing under different coaches and systems is part and parcel of all professional footballers' lives. We've been doing that since we were kids. I don't think it's that difficult, but of course, we all need to be on the same tune, and play with the same mentality," Bose added.
Business Standard
12-05-2025
- Business
- Business Standard
Aarti Pharmalabs Q4 PAT climbs 35% YoY to Rs 88 cr
Aarti Pharmalabs reported 35.38% increase in consolidated net profit to Rs 88.34 crore in Q4 FY25 as against Rs 65.25 crore posted in Q4 FY24. Revenue from operations jumped 11.46% YoY to Rs 563.78 crore in the quarter ended 31 March 2025. Profit before tax was at Rs 114.62 crore in the fourth quarter of FY25, up 19.70% from Rs 95.75 crore posted in the same period a year ago. Total expenses increased 8.61% to Rs 447.55 crore in Q4 FY25, compared to Rs 412.05 crore reported in Q4 FY24. The cost of material consumed stood at Rs 185.45 crore (down 7.97% YoY), employee benefit expenses were at Rs 43.37 crore (up 43.37% YoY) and finance costs stood at Rs 6.58 crore (up 40.59% YoY) during the period under review. On a full-year basis, the companys net profit rose 25.58% to Rs 272.40 crore on a 14.16% increase in revenue to Rs 2,115.07 crore in FY25 over FY24. The company's board has recommended a dividend of Rs 2.5 per equity share for the financial year 2024-25. Subject to the approval of the shareholders at the ensuing annual general meeting of the company. Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), and xanthine derivatives situated in India. The counter declined 1.33% to Rs 757.15 on the BSE.
Associated Press
06-05-2025
- Business
- Associated Press
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
WARRINGTON, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ('Windtree' or the 'Company') (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions and diseases, is pleased to announce it has received advice from intellectual property and FDA experts highlighting a U.S. strategy that can provide 7.5 years of U.S. exclusivity for istaroxime if it is approved by the FDA in cardiogenic shock. Specifically, as a never-before-approved active ingredient, istaroxime may receive New Chemical Entity (NCE) designation from the FDA. If the new drug application is approved with such a designation, istaroxime would be entitled to 5 years of data exclusivity, and a stay of FDA approval of any generic application equal to 7.5 years from the date of istaroxime's FDA approval should any generic company challenge the patents that Windtree has obtained or is pursuing and if Windtree files a patent infringement lawsuit in response to such a challenge. Istaroxime also has a USPTO issued method of use patent providing protection until 2039 and a pending method of use patent providing protection until 2043. 'We believe that the NCE exclusivity strategy is an attractive approach if istaroxime receives FDA approval in cardiogenic shock,' said Jed Latkin, Chief Executive Officer of Windtree. 'It would be combined with our method of use patents for istaroxime in the U.S.' Mr. Latkin continued, 'We continue our focused development and IP strategic planning for istaroxime in cardiogenic shock and our next milestone is a planned interim analysis of our Phase 2 cardiogenic shock SCAI Stage C study in Q3, 2025.' The istaroxime SCAI Stage C study (SEISMiC C) is a global trial including sites in the U.S. Europe and Latin America. It is a placebo-controlled, double-blinded study with istaroxime being added to current standard of care, inotropes or vasopressors. The effect of istaroxime in addition to these therapies will be assessed for 6 hours and based on the patient's condition, a withdrawal of the other therapies. The primary endpoint of the study is assessment of systolic blood pressure (SBP) profile over the first 6 hours of treatment. Other key study measurements include various measures of cardiac function, SBP changes at specified timepoints, the vasopressor-inotrope score, avoidance of progression to SCAI Stage D or E cardiogenic shock and need for mechanical cardiac support, time to treatment failure, arrhythmia assessments, days alive and out of the hospital through day 30, physiologic measures (e.g., cardiac index) and length of stay in the intensive care unit and hospital. About Istaroxime Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure demonstrate that istaroxime infused intravenously significantly improves cardiac function and blood pressure without increasing heart rate or the incidence of cardiac rhythm disturbances. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree's portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking Statements This press release contains statements related to the acquisition of the real estate property discussed above; rental revenue if such property is acquired; potential clinical effects of istaroxime; the potential benefits and safety of istaroxime; the clinical development of istaroxime; and our research and development program for treating patients in early cardiogenic shock due to heart failure. Such statements constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'proposed,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, among other things: the Company could lose its deposit on the real estate property discussed above; the Company may fail to acquire such real estate property; the Company's ability to acquire revenue generating subsidiaries; the market's reaction to potential acquisitions by the Company; the Company's ability to secure significant additional capital as and when needed; the Company's ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company's other product candidates, including preclinical oncology candidates; the Company's ability to access the debt or equity markets; the Company's ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company's product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company's efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates, if approved; the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People's Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company's operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company's ability to access the capital markets. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Eric Curtis [email protected]
